DRMA Quote, Financials, Valuation and Earnings

Aptevo Therapeutics, Inc. has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of --. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat Aptevo Therapeutics, Inc.'s return on equity of -442.03%.

Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 367.29%. On the other hand Aptevo Therapeutics, Inc. has an analysts' consensus of $21.00 which suggests that it could grow by 4008.69%. Given that Aptevo Therapeutics, Inc. has higher upside potential than Dermata Therapeutics, Inc., analysts believe Aptevo Therapeutics, Inc. is more attractive than Dermata Therapeutics, Inc..

Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aptevo Therapeutics, Inc. has a beta of 1.473, suggesting its more volatile than the S&P 500 by 47.266%.

Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aptevo Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. Aptevo Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dermata Therapeutics, Inc. quarterly revenues are --, which are smaller than Aptevo Therapeutics, Inc. quarterly revenues of --. Dermata Therapeutics, Inc.'s net income of -$1.7M is higher than Aptevo Therapeutics, Inc.'s net income of -$9M. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while Aptevo Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus 0.04x for Aptevo Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Citius Pharmaceuticals, Inc. has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of --. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat Citius Pharmaceuticals, Inc.'s return on equity of -56.5%.

Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 367.29%. On the other hand Citius Pharmaceuticals, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 566.67%. Given that Citius Pharmaceuticals, Inc. has higher upside potential than Dermata Therapeutics, Inc., analysts believe Citius Pharmaceuticals, Inc. is more attractive than Dermata Therapeutics, Inc..

Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Pharmaceuticals, Inc. has a beta of 1.565, suggesting its more volatile than the S&P 500 by 56.483%.

Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. Citius Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Dermata Therapeutics, Inc. quarterly revenues are --, which are smaller than Citius Pharmaceuticals, Inc. quarterly revenues of --. Dermata Therapeutics, Inc.'s net income of -$1.7M is higher than Citius Pharmaceuticals, Inc.'s net income of -$8.7M. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while Citius Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus -- for Citius Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Dynavax Technologies Corp. has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of 28.38%. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat Dynavax Technologies Corp.'s return on equity of -7.65%.

Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 367.29%. On the other hand Dynavax Technologies Corp. has an analysts' consensus of $20.50 which suggests that it could grow by 33.03%. Given that Dermata Therapeutics, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Dermata Therapeutics, Inc. is more attractive than Dynavax Technologies Corp..

Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dynavax Technologies Corp. has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.879%.

Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynavax Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. Dynavax Technologies Corp. pays out -- of its earnings as a dividend.

Dermata Therapeutics, Inc. quarterly revenues are --, which are smaller than Dynavax Technologies Corp. quarterly revenues of $94.9M. Dermata Therapeutics, Inc.'s net income of -$1.7M is lower than Dynavax Technologies Corp.'s net income of $26.9M. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while Dynavax Technologies Corp.'s PE ratio is 54.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus 6.44x for Dynavax Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Ekso Bionics Holdings, Inc. has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of -33.62%. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat Ekso Bionics Holdings, Inc.'s return on equity of -85.7%.

Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 367.29%. On the other hand Ekso Bionics Holdings, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 16%. Given that Dermata Therapeutics, Inc. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe Dermata Therapeutics, Inc. is more attractive than Ekso Bionics Holdings, Inc..

Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ekso Bionics Holdings, Inc. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 29.033%.

Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ekso Bionics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. Ekso Bionics Holdings, Inc. pays out -- of its earnings as a dividend.

Dermata Therapeutics, Inc. quarterly revenues are --, which are smaller than Ekso Bionics Holdings, Inc. quarterly revenues of $4.2M. Dermata Therapeutics, Inc.'s net income of -$1.7M is lower than Ekso Bionics Holdings, Inc.'s net income of -$1.4M. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while Ekso Bionics Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus 7.61x for Ekso Bionics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.